Bactiguard®

Interim report Q3 2024 presentation

Thursday 24 October 2024

Christine Lind, CEO Patrick Bach, CFO



Q3 SUMMARY

Delivers positive EBITDA and initiates review of 2028 financial targets due to previously announced agreement termination

Q3 2024 key figures and highlights

Bactiguard turns profitable on EBITDA level in third quarter

Key figures Q3 2024 (Q3 2023)

Revenues	73.9 (49.5) MSEK
EBITDA	9.9 (-9.5) MSEK
Net Loss	-4.7 ▼ (-24.6) MSEK
CF from operating activities	8.3 (-35.0) MSEK

Highlights from Q3

- Profitability on EBITDA level
- Solid growth in BD main driver of EBITDA
- Strong third quarter for Wound Management


Events after the quarter

• Review of 2028 financial targets – outcome to be communicated in Q1 2025

Advanced infection prevention technology

Reduces microbial adhesion and biofilm formation on medical devices

- Biocompatible, safe and proven reduces the risk of medical device related infections
- Ultra-thin noble metal coating technology; gold, silver and palladium
- In contact with fluids, the noble metals create a galvanic effect due to their varying electro potentials
- More than **100,000 patients** included in clinical trials
- Efficacy assessed in more than **40 clinical studies**
- Studies cover various patient cohorts, regions, and therapeutic areas



Critical global healthcare trends driving market needs

The issues


- Antimicrobial resistance one of the top global public health threats facing humanity – associated with the death of close to 5 million people globally in 2019
- 1 in 10 patients worldwide affected by healthcare associated infections
- Demographic development, ageing population and increasing lifestyle diseases
- Political unrest, conflicts, wars and natural disasters
- Demand for more efficient and safe healthcare

The market opportunity (USD 80bn)




Effective license focused strategy and business model

Increased interest in our infection prevention technology from MedTech companies



Business model and partner journey

Three types of revenues – partners generating exclusivity and license revenues are communicated



Solid BD growth drives EBITDA for Q3

Global partnership approach – BD's success is Bactiguard's success

- Revenues from BD collaboration main driver of EBITDA
- Close collaboration on expansion of Bactiguard-coated Foley catheters into both existing and new markets
- Engagement across the entire value chain from technology to go-to-market

At a glance



- Q3 revenues: 33.3 MSEK
- Partnership since early 90s 230 million Foleys coated catheters sold
- Exclusive global license for coated Foley catheters (ex China)



Zimmer Biomet trauma agreement remains in effect

Infection rates and medical need significantly higher in trauma segment

- Termination of the multiple orthopedic product segment
 agreement announced early October
- Ongoing trauma collaboration also includes work with regulatory processes in Europe and the US
- Commercialization activities for **ZNN Bactiguard trauma nail** continued, especially in Europe

At a glance



- Q3 revenues: 10.3 MSEK
- Global leader in orthopedics
- Agreement covers trauma implant segment (signed in 2019)







Wound Management by Bactiguard

Preventing infections by offering effective, biocompatible solutions to improve wound healing

- Continued **path of profitable growth** during the third quarter
- Published results of randomized study in peritoneal and wound lavage* – reduced overall surgical-site infections by 58%, and superficial surgical-site infections by 72%

At a glance



- Q3 revenues: 17.9 MSEK
- Offering includes Hydrocyn aqua (enabling wound healing and preventing infections) and a wide range of surgical sutures



10

^{*} Source: Effect of peritoneal and wound lavage with super-oxidized solution on surgical-site infection after open appendicectomy in perforated appendicitis (PLaSSo): randomized clinical trial | BJS Open | Oxford Academic


Total revenue Q3 2024

Solid growth in license revenues, notably from BD partnership


	Jul-Sep		Jan-Sep		Full year	RTM
MSEK	2024	2023	2024	2023	2023	2023/24
Total license revenue	47.5	20.8	120.5	85.0	117.2	152.6
License partners	46.6	6 18.0	114.2	74.8	104.3	143.7
Exclusivity partners		- 2.7	5.3	7.1	9.7	7.9
Application development partners	0.9	0.2	1.0	3.2	3.2	1.0
Wound Management portfolio	17.9	9 17.5	45.3	39.9	53.8	59.2
BIP portfolio	1.9	97.1	12.8	20.4	30.5	23.0
Net sales	67.3	3 45.5	178.6	145.3	201.5	234.9
Other operating revenues	6.6	6 <u>4</u> .0	15.0	16.5	21.6	20.1
Total revenue	73.9	9 49.5	193.6	161.8	223.2	255.0

- Total license revenue amounted to 47.5 (20.8) MSEK
- Revenues from BD amounted to 33.3 (9.2) MSEK
- Revenues from Zimmer Biomet amounted to 10.7 (11.6) MSEK
- Revenues from Wound Management amounted to 17.9 (17.5) MSEK
- Revenues from BIP amounted to 1.9 (7.1) MSEK
- Total revenue amounted to 73.9 (49.5) MSEK. Adjusted for currency of 0.4 MSEK, revenue increased by 48.7 percent in Q3
- For Jan-Sep, total revenue amounted to 193.6 (161.8) MSEK. Adjusted for currency of 7.6 MSEK, revenue increased 15.0 percent

Net sales grew 48% in Q3 and 23% YTD, driven by solid growth in license revenues



EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD



Total operating expenses and cash flow Q3 2024

On track to deliver cost savings exceeding 25 MSEK on a yearly basis following the transformation

Operating expenses

- Costs for raw materials and consumables amounted to -6.9 (-10.5) MSEK, a decrease of 3.7 MSEK
- Other external costs amounted to -27.8 (-21.6) MSEK, an increase of 6.3 MSEK
- Personnel costs amounted to -24.9 (-25.0) MSEK, a decrease of 0.1 MSEK
- Other operating expenses amounted to -4.1 (-3.2) MSEK, an increase of 0.9 MSEK
- In Q3, total OPEX amounted to -56.9 (-49.8) MSEK, an increase of 7.1 MSEK
- YTD, total OPEX amounted to -153.5 (-185.1) MSEK, a decrease of 31.6 MSEK

Cash flow

- Cash flow from operating activities amounted to 8.3 (-35.0) MSEK
- Cash flow from investing activities amounted to -2.9 (-0.7) MSEK
- Cash flow from financing activities amounted to -3.9 (-3.0) MSEK
- In Q3, total cash flow amounted to 1.6 (-38.7) MSEK
- YTD, total cash flow amounted to -20,5 (-73.0) MSEK
- Cash and cash equivalents at the end of the quarter was 106.4 (124.4) MSEK

Our priorities ahead – focus is still in focus

Vision: become the global standard of care for preventing medical device related infections

- Advance current partnerships with BD, Zimmer Biomet and Well Lead
- New partnerships in strategic therapeutic areas convert early-stage projects into exclusivity and license partnerships
- Continue profitable growth of Wound Management
- Build competencies within the knowledge and specialist organization further
 - corporate culture
 - specialist areas (R&D, coating, medical, commercial, and regulatory)
- Continue to deliver profitability and sustainable growth





to champion a healthier world by preventing infections

Questions & Answers

End of Q3 2024 presentation



Christine Lind CEO



Patrick Bach CFO

